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Exclusion of eight genes as mutated loci in congenital nephrotic
syndrome of the Finnish type. The congenital nephrotic syndrome of the
Finnish type (CNF) is an autosomal recessive disease characterized by
massive proteinuria already at birth. The gene locus defective in CNF
was searched for using polymorphic markers of candidate genes coding
for components of the basement membrane (BM). The linkage analyses
in 17 Finnish CNF families demonstrated exclusion or obligatory
recombination events between the disease and eight genes coding for
BM components. The genes coding for the nl(IV), a2(IV), a3(IV) and
a4(IV) chain of type IV collagen, the B le, B2e and B2t chains of
laminin, as well as the BM heparan sulfate proteoglycan core protein
were all excluded in this Finnish family material. Since the defect is not
in any of the genes coding for major components of BM, the identifi-
cation of the gene defect will most probably reveal a new gene
important for the development and function of the glomerular basement
membrane.
Congenital nephrotic syndrome of the Finnish type (CNF) is
an autosomal, recessively inherited disease, which is character-
ized by massive proteinuria, starting already in utero, a large
placenta (over 25% of birth weight), and nephrotic syndrome
from birth [1, 2]. This disorder is unusually common in Finland,
and belongs to the group of the —30 diseases known as the
Finnish disease inheritage, due to their exceptionally high
incidence in this genetically isolated population. The incidence
of CNF in Finland is about 12 per 100,000 live-born children [3].
The disorder can be diagnosed prenatally by elevated levels of
a-fetoprotein in amniotic fluid or maternal serum [4]. Previously
the patients were highly suspectible to infections and vascular
complications, growth and development were retarded, and the
patients usually died within the first two years of life. Today,
normal growth and development can be achieved with intrave-
nous protein substitution and nutritional support followed by
nephrectomy, dialysis and renal transplantation [5—7]. The main
histopathological changes in CNF kidneys are dilated cortical
tubules, areas of tubular atrophy, interstitial fibrosis, mesangial
cell proliferation and sclerosis and fibrosis of the glomeruli [8].
Electron microscopy studies have not revealed pathognomonic
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changes in the glomerular basement membrane (GBM). The
pathogenesis of the disease is unknown, but the massive
proteinuria and normal development of patients following kid-
ney transplantation, without any extrarenal manifestations [7,
9], implies that the gene defect involves a protein highly specific
for the function or development of the glomerular filtration
barrier.
The actual glomerular filtration barrier for blood macromol-
ecules consist of the —3000 to 3500 nm thick GBM which is
located between the fenestrated capillary endothelial cells and
the epithelial podocytes. The epithelial foot processes, which
are separated from each other by the slit pores, only partially
cover the GBM. A thin diaphragm, whose chemical composi-
tion is unknown, covers the GBM between the foot processes.
Like all basement membranes (BM), the GBM is formed by
structural networks of type IV collagen and laminin into which
other components such as heparan sulfate proteoglycan (perle-
can) and entactin are bound [10].
Type IV collagen is the major structural component of BMs.
The molecule is typically a heterotrimer consisting primarily of
two al(IV) chains and one a2(IV) chain. The corresponding
genes are located adjacent to each other at 1 3q34 [11, 12].
Lower abundance type IV collagen variants contain a3(IV) and
a4(IV) chains whose genes, COL4A3 and COL4A4, have both
been localized to 2q35-q37 [13, 14]. The COL4A5 gene of a fifth
minor a5(IV) chain has been localized to Xq22 [15]. Mutations
in COMAS have been shown to cause X chromosome-linked
Alport syndrome (hereditary nephritis), a disease characterized
by hematuria [16, 17].
Laminins are a family of trimeric basement membrane spe-
cific glycoproteins composed of A, B 1 and B2 type chains in a
stoichiometric ratio. Thus far, two variants of each laminin
chain have been identified. The genes for the chain variants
have been assigned as follows: LAMA for the Ae chain to
l8pll.3 [18], LAMAM for the Am chain to 6q22-q23 [191,
LAMB1 for the Ble chain to 7q22 [20], LAMB2 for the B2e
chain to 1q25-31 [21], and LAMB2T to 1q25-q31 [22].
The gene for the basement membrane heparan sulfate pro-
teoglycan, also termed perlecan, has been proposed as the
primary candidate gene for CNF. Due to its highly anionic
properties, this component is believed to provide an electric
hindrance for the traversal of macromolecules through the
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Fig. 1. Pedigrees of the Finnish CNFfa,nilies (* no sample available, ** affection status unknown).
GBM into the urinary space [23]. A decrease in the content of
GBM heparan sulfate has been reported in experimental and
congenital nephrotic syndromes [241, and these results led to
the hypothesis that a decrease in perlecan or the heparan sulfate
content of its core protein can facilitate the penetration of large
proteins through the GBM. However, no decrease in heparan
sulfate content has been found in several Finnish patients with
CNF [25]. The gene for the 467 kDa core protein of human
perlecan has been localized to lp36.l-p35 [26]. Yet another BM
specific protein, entactin, has been cloned and its gene assigned
to 1q43 [27].
Although no specific biochemical or cytogenetic alterations
have thus far been demonstrated in CNF individuals, it is quite
likely that the primary defect in CNF involves an abnormality
of some of the components of the glomerular filtration barrier.
In an attempt to identify the gene defect in CNF we have
applied linkage analyses in 17 Finnish families and followed the
inheritance of polymorphisms of genes encoding eight compo-
nents of basement membranes to test if any of these would
co-segregate with the disease.
Methods
Pedigrees and preparation of DNA
Genomic DNA from members of 29 Finnish families with
CNF representing all available CNF families in Finland were
used in this study, The pedigrees of 17 families which have one
or two affected children, and one to nine healthy siblings are
illustrated in Figure 1. The remaining 12 families have only one
affected child and these families were not used in the linkage
analyses. Cell lines of skin fibroblasts or lymphocytes immor-
talized by the Epstein-Barr virus were established. A total of
123 cell lines were established, 32 of which were from individ-
uals diagnosed with classical CNF. Genomic DNA was ex-
tracted from cultured cells using an automated Applied Biosys-
tems Inc. 340A DNA extractor. The diagnosis of CNF was
based on the typical clinical picture with massive proteinuria
from birth, a large placenta (>25% of birth weight) and exclu-
sion of other types of congenital nephrotic syndrome [28]. The
typical renal histology was confirmed at nephrectomy.
RFLPs, hybridization probes and SSCP analysis
Intragenic RFLPs (restriction fragment length polymor-
phism) of eight genes encoding basement membrane compo-
nents were analyzed in Finnish CNF families. The COL4A5
collagen gene, located on the X chromosome, is excluded as a
causal factor in the autosomal recessive CNF based on the
structure of the pedigrees. Intragenic RFLPs and cDNA probes
detecting them were used as follows: For type IV collagen
genes a Hindu! RFLP in COMAI was detected with the HT-2l
cDNA [29], a TaqI RFLP in COL4A2 detected with HT-39 [301
and a BamHI RFLP in COL4A4 detected with PCR 100-19-6
cDNA (S. Reeders, personal communication). For the laminin
genes, HL-4042 cDNA was used for a HpaI RFLP in LAMB1
[31], HL-210 cDNA for a PstI RFLP in LAMB2 [32] and L-52
eDNA for a PstI RFLP in LAMB2T (Minna MannikkO, unpub-
lished observations). The cDNA clone HT-2/l for perlecan was
used to detect a BamHI RFLP [26]. An SSCP polymorphism
was detected in the COL4A3 gene using F5 and R5 primers (S.
Reeders, personal communication).
For the RFLP analyses DNA was digested with restriction
endonucleases under appropriate conditions, electrophoresed
on 1.0% agarose gels and transferred to nylon filters (Hybond-
N). Hybridization was carried out using nick-translated cDNA
probes followed by autoradiography.
An SSCP (single strand conformation) polymorphism in the
COL4A3 collagen gene was detected by using PCR amplifica-
tion followed by non-denaturing polyacrylamide gel electro-
phoresis. The PCR was performed in 25 tl containing —30 ng of
template DNA, 25 pmoles of primers (F5 and R5), 0.2 m of
each nucleotide, 1.0 U of Thermus aquaticus DNA polymerase
(Promega) and 1.0 Ci a-32P dCTP in a buffer consisting of 20
mM Tris HC1 (pH 8.8), 15 mM (NH2)S04, 1.5 mM MgCl2, 0.1%
and Tween 20, 0.01% gelatin. The PCR reactions were per-
formed in multiwell microtiter plates for 30 cycles with dena-
turation at 94°C for one minute, annealing at 56°C for one
minute, and an extension at 72°C for one to five minutes. Prior
to gel electrophoresis, 4 l of the PCR products were digested
with 20 U of RsaI restriction enzyme under approriate condi-
tions in a total volume of 50 d. Samples containing 1 1d of 0.6%
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Table 1. Linkage analyses between CNF and genes coding for BM components
Protein Gene Chrom. locus
lod score at 9 of
0.00 0.01 0.05
Type IV collagen
al COL4AI 13q34 —oo —2.13 —1.27
a2 COL4A2 l3q34 —cc —1.80 —1.03
a3 COL4A3 2q35-q37 —cc —1.73 —0.98
a4 COL4A4 2q35-q37 —cc —2.98 —1.60
Laminin
Ble LAMBI 7q22/31 —cc —0.14 +0.40
B2e LAMB2 1q25-q31 —cc —2.85 —1.46
B2t LAMB2T 1q31 —cc —1.90 —1.09
Perlecan HSPG2 1p36.l-p35 —cc —1.95 —1.17
SDS and 0.06 M EDTA were added to 5 d of the digested PCR
product and 6 .d of a solution containing 95% formamide, 20
mM EDTA, 0.05% bromphenol blue and 0.05% xylene cyanol
was added. The sample was denatured at 80°C for three minutes
and 5 d of the sample were applied to a nondenaturing 5%
polyacrylamide gel consisting of 5% glycerol in 4 mivi Tris-
borate, 2 mri EDTA and 1/2 x TBE buffer. The gel was run at
16 W for 15 hours at room temperature. The gel was dried and
autoradiography was performed for 24 hours with Kodak
X-omat AR films using intensifying screens.
Linkage analysis
Linkage analyses were used to test if CNF is linked to some
of the known genetic loci encoding basement membrane com-
ponents. In linkage analysis the lod scores are obtained by
calculating the likelihood that two loci are linked versus the
hypothesis that they are unlinked at a given recombination
fraction. An odds ratio of more than 1000:1 (the base 10
logarithm of the odds is lod score > + 3) favoring linkage is
taken as proof of linkage, and an odds ratio less than 1:100 (lod
score <—2) is considered to indicate exclusion of the particular
locus as the site of disease mutation. Linkage analyses were
carried with the LINKAGE computer program (version 5.10)
[331. Complete penetrance of the disease was assumed in the
analyses because the age of onset of the disease is the first
months of life. Disease gene frequency of 0.01 was adapted
based on the population incidence of CNF in Finland.
Results
Exclusion of the perlecan gene (HSPG2)
Human perlecan is a basement membrane specific proteogly-
can with a 467 kDa core protein containing attachment sides for
three large heparan sulfate side chains at its amino terminal end
[341. For years, the gene for this component has been consid-
ered as the prime candidate gene in CNF, because proteinuria
has been associated with decreased content of heparan sulfate
in the GBM [241. The analysis of the intragenic RFLP in the
Finnish CNF families revealed a minimum of one obligatory
recombination event between the marker and the disease (Table
1). Consequently, the perlecan gene can be considered ex-
cluded as a mutated locus in CNF.
Although the present results exclude the gene for the perle-
can core protein in CNF, an abnormality in perlecan cannot
completely be excluded in the disease. One possibility is that
one of the enzymes required for post-translational linking of
polysaccharides to the core protein is affected. However, since
these enzymes are probably needed for modification of different
heparan sulfate proteoclycans in other tissues, their defect is
not likely to result in a malfunction specifically occurring in the
GBM.
Type IV collagen
Results of linkage analyses for four type IV collagen a chain
genes are shown in Table 1. At least one recombination event
was obtained between the CNF and these genes, thus excluding
mutations in this collagen type as the cause of CNF. The
exclusion of the genes for a al(IV), a2(IV), cs3(IV) and a4(IV)
collagen chains was somewhat expected. The triple-helical type
IV collagen molecule, which exists in different isoforms, forms
the structural network of basement membranes in all tissues
[101. Additionally, a defect in any type IV collagen chain
component is likely to result in so gross structural abnormalities
of any BM that they should be visible by electron microscopy.
Such has been shown to be the case in X-linked Alport
syndrome [16, 17, 35], where defects in the quite GBM specific
a5(IV) chain result in lamellation and splitting of the GBM as
observed by electron microscopy. However, in CNF no pri-
mary morphological changes are seen in the GBM, the only
finding being severe functional abnormality with massive leak-
age of plasma proteins into the urine [5, 361.
Laminin
Pairwise linkage analysis of the intragenic markers of
LAMB 1, LAMB2 and LAMB2T genes revealed a minimum of
one obligatory recombination event between CNF and each
corresponding candidate gene, and consequently these genes
can also be excluded as mutated loci in CNF (Table 1).
Although a possibility remains that the genes coding for the Ae,
Am and Bis chains of laminin would be linked to CNF, this is
not likely since these proteins are known not to be very specific
for the GBM, the only BM demonstrating functional deficiency
in this disease.
Discussion
In the present study we have excluded eight genes coding for
major basement membrane components as causative loci in
CNF. In most cases only one recombination event was obtained
between the candidate gene and the marker, to a large extent
due to the low heterozygosity of intragenic RFLP markers and
the relatively small family material. However, because CNF is
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highly enriched in the isolated Finnish population and only a
few cases are known in other countries, it can be assumed that
CNF in these families represents a homogeneous disease and
that one major mutation will be found in Finnish CNF cases.
Consequently, one recombination event can be considered
sufficient to exclude each candidate gene in question.
On the basis of the present results and the above, it now has
to be considered likely that the CNF gene defect involves a thus
far unknown protein which is important and possibly specific
for kidney development or purely GBM filtration. In fact,
inactivation of two unrelated genes in transgenic mice has been
reported to lead to congenital nephrotic syndrome-like pheno-
types. Thus, Weiher et al [37] described the development of
nephrotic syndrome and chronic renal failure by inactivation of
the ubiquitously expressed Mpvl7 gene. Furthermore, Dressler
et al [38] demonstrated that deregulation of Pax-2, a transcrip-
tion factor expressed in induced kidney mesenchyme, ureter
epithelium and in early epithelial structures, led to congenital
nephrotic syndrome. The human genes for Mpvl7 and Pax-2
have been localized to chromosomes 2 and 10, respectively
(Hans Weiher, personal communication, [39]), and we have
also excluded these genes as mutated loci in CNF using
chromosomal markers [40]. It has been assumed that the
protein defective in CNF represents a BM component essential
for kidney development because of heavy proteinuria and high
tissue specificity of disease, but for example Ljungberg eta! [41]
have recently reported that major qualitative changes of GBM
components were not observed in CNF kidneys to explain the
massive proteinuria. In order to identify the CNF gene we have,
therefore, initiated studies using random mapping method with
highly informative amplifiable polymorphisms to assign the
CNF locus in the specific chromosomal region in the human
genome. The results of this search should reveal a gene that
would code for a component important for normal development
and function of the GBM. Such a gene could encode a novel
structural GBM component, but also some important regulator
of cell growth and development, as exemplified by identification
of constitutional mutations of a tumor suppressor gene (WT1) in
Denys-Drash syndrome with typical nephropathy and severe
urogenital aberrations resulting in renal failure [42, 43].
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